Cardiff Oncology Inc (FRA:XE7C)
€ 2.975 -0.145 (-4.65%) Market Cap: 142.29 Mil Enterprise Value: 82.00 Mil PE Ratio: 0 PB Ratio: 2.53 GF Score: 50/100

Q4 2023 Cardiff Oncology Inc Earnings Call Transcript

Feb 29, 2024 / 09:30PM GMT
Release Date Price: €1.64 (+2.24%)
Operator

Welcome to the Cardiff Oncology fourth-quarter and full-year 2023 financial results and corporate update conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to turn the conference over to Laurence Watts, the Gilmartin Group. Please go ahead.

Laurence Watts
Gilmartin Group LLC - IR

Thank you, operator. Joining us on the call today from Cardiff Oncology are Chief Executive Officer, Mark Erlander; Chief Medical Officer, Dr. Fairooz Kabbinavar; and Chief Financial Officer, Jamie Levine.

During this conference call, management will make forward-looking statements, including, without limitation, statements related to guidance, results, and the timing of data readouts for onvansertib clinical trials. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties.

Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot